Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
NCT03883412
Summary
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.
Eligibility
Inclusion Criteria: * Age 21-60 * A1C ≤ 8.5% * Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton) * On stable dose of oral hypoglycemic agents \>4 months * On stable dose of other medications for \>4 months Exclusion Criteria: * Taking Insulin * Smoking presently or in the past 6 months * BP \>160/90 * BMI \>35 * Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome * History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease. * Any vascular disease such as myocardial infarction, stroke, peripheral vascular disease * Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI). * Pregnant or breastfeeding. * Known hypersensitivity to perflutren (contained in Definity)
Conditions2
Interventions1
Locations1 site
Find trials near these locations
Related trials
- Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control — Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) — The First Affiliated Hospital of Xiamen University
- Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus — Biolingus
- Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY) — Mansa
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT03883412